Literature DB >> 25843268

Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?

R Michel1, F Berger2, J Ravelonarivo3, P Dussart4, M Dia5, M Nacher6, S Rogier7, D Moua4, F D Sarr5, O M Diop5, A A Sall5, L Baril8.   

Abstract

BACKGROUND: The use of 2 live attenuated vaccines (LAV) is recommended to be simultaneous or after an interval of at least four weeks between injections. The primary objective of this study was to compare the humoral response to yellow fever (YF) and measles vaccines among children vaccinated against these two diseases, either simultaneously or separated by an interval of 7-28 days. SUBJECTS AND METHODS: A prospective, multicenter observational study was conducted among children aged 9-15 months. The primary endpoint was the occurrence of positive yellow fever antibodies after YF vaccine by estimating the titers of neutralizing antibodies from venous blood samples. Children vaccinated against YF 7-28 days after receiving the vaccine against measles (test group) were compared with children vaccinated the same day against these two diseases (referent group).
RESULTS: Analysis was performed on 284 children. Of them, fifty-four belonged to the test group. Measles serology was positive in 91.7% of children. Neutralizing antibodies against YF were detected in 90.7% of the test group and 92.9 of the referent group (p=0.6). In addition, quantitative analysis of the immune response did not show a lower response to YF vaccination when it took place 1-28 days after measles vaccination. DISCUSSION: In 1965, Petralli showed a lower response to the smallpox vaccine when injected 4-20 days after measles vaccination. Since then, recommendations are to observe an interval of four weeks between LAV not injected on the same day. Other published studies failed to show a significant difference in the immune response to a LAV injected 1-28 days after another LAV. These results suggest that the usual recommendations for immunization with two LAV may not be correct.
CONCLUSION: In low income countries, the current policy should be re-evaluated. This re-evaluation should also be applied to travelers to yellow fever endemic countries.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Active immune response; Live attenuated vaccine; Measles; Yellow fever

Mesh:

Substances:

Year:  2015        PMID: 25843268     DOI: 10.1016/j.vaccine.2015.03.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo.

Authors:  Alexandra C Willcox; Matthew H Collins; Ramesh Jadi; Corinna Keeler; Jonathan B Parr; Dieudonné Mumba; Melchior Kashamuka; Antoinette Tshefu; Aravinda M de Silva; Steven R Meshnick
Journal:  Am J Trop Med Hyg       Date:  2018-07-05       Impact factor: 2.345

Review 2.  SARS-CoV-2 Liability: The Hidden Mystery Behind Its Presentation in Children.

Authors:  Reza Jafarzadeh Esfehani; Mohammad Hassan Aelami; Afsaneh Rezaei Kalat; Saman Soleimanpour; Zahra Pasdar; Majid Khazaei; Alireza Pasdar; Amir Avan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.

Authors: 
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-09       Impact factor: 2.743

4.  Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.

Authors:  Panchali Roy Chowdhury; Christian Meier; Hewad Laraway; Yuxiao Tang; Abraham Hodgson; Samba O Sow; Godwin C Enwere; Brian D Plikaytis; Prasad S Kulkarni; Marie-Pierre Preziosi; Matthias Niedrig
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

5.  Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study.

Authors:  Cristina Domingo; Juliane Fraissinet; Patrick O Ansah; Corey Kelly; Niranjan Bhat; Samba O Sow; José E Mejía
Journal:  Lancet Infect Dis       Date:  2019-09-19       Impact factor: 25.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.